Jeffrey M. Jonas - 03 Jul 2023 Form 4 Insider Report for Karuna Therapeutics, Inc.

Role
Director
Signature
/s/ Troy Ignelzi, Attorney-in-Fact
Issuer symbol
N/A
Transactions as of
03 Jul 2023
Net transactions value
-$2,888,400
Form type
4
Filing time
05 Jul 2023, 16:44:08 UTC
Previous filing
22 Jun 2023
Next filing
02 Aug 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction KRTX Common Stock Options Exercise $100,399 +13,810 +1395% $7.27* 14,800 03 Jul 2023 Direct F1
transaction KRTX Common Stock Sale $50,219 -234 -1.6% $214.61 14,566 03 Jul 2023 Direct F1, F2
transaction KRTX Common Stock Sale $1,719,939 -7,966 -55% $215.91 6,600 03 Jul 2023 Direct F1, F3
transaction KRTX Common Stock Sale $693,913 -3,201 -48% $216.78 3,399 03 Jul 2023 Direct F1, F4
transaction KRTX Common Stock Sale $524,728 -2,409 -71% $217.82 990 03 Jul 2023 Direct F1, F5

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction KRTX Option (right to buy) Options Exercise $0 -13,810 -23% $0.000000 47,512 03 Jul 2023 Common Stock 13,810 $7.27 Direct F1, F6
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Buy Plan / Sale Plan: These are also open market purchases/sales of shares, but in this case the transaction is part of a trading plan. Rule 10b5-1 allows insiders to setup a trading plan to buy/sell stocks over a certain period of time. Since the purchases/sales are predetermined, this protects the insiders from violating insider trading law.

Transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c).

Explanation of Responses:

Id Content
F1 The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 28, 2023.
F2 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $214.05 to $214.81, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in footnotes (2) through (5) to this Form 4.
F3 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $215.34 to $216.33, inclusive.
F4 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $216.37 to $217.35, inclusive.
F5 The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $217.42 to $218.29, inclusive.
F6 This option vested and became exercisable in eight equal installments on each six month anniversary of the vesting commencement date of September 20, 2018.